Comparative effectiveness of cycling of tumor necrosis factor-${alpha}$ (TNF-${alpha}$) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-${alpha}$ inhibitor using a Bayesian approach

Kim, Hye-Lin; Lee, Min-Young; Park, Sun-Young; Park, Sun-Kyeong; Byun, Ji-Hye; Kwon, Sunhong; Lee, Eui-Kyung

추천

검색

자료유형: 학술저널

저자정보: Kim, Hye-Lin (School of Pharmacy, Sungkyunkwan University) Lee, Min-Young (School of Pharmacy, Sungkyunkwan University) Park, Sun-Young (School of Pharmacy, Sungkyunkwan University) Park, Sun-Kyeong (School of Pharmacy, Sungkyunkwan University) Byun, Ji-Hye (School of Pharmacy, Sungkyunkwan University) Kwon, Sunhong (School of Pharmacy, Sungkyunkwan University) Lee, Eui-Kyung (School of Pharmacy, Sungkyunkwan University)

저널정보: 대한약학회 Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea 제37권 제5호

발행연도: 2014.1

수록면: 662 - 670 (9page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Alternative tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$) inhibitors and non-TNF biologics are available as treatment options for rheumatoid arthritis patients who exhibit inadequate response to TNF-${\alpha}$ inhibitor (TNF-IR patients). These agents have considerable efficacy compared with placebo, but head-to-head comparisons among these agents have not been performed. The objective of this study was to use Bayesian approach to compare the effectiveness of cycling TNF-${\alpha}$ inhibitors versus switching to non-TNF biologics in TNF-IR patients. A systematic review was conducted using MEDLINE and Cochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 and the health assessment questionnaire (HAQ) score change at six months. Bayesian outcomes were calculated as the probability that OR is greater than one and HAQ score change difference is less than zero. Compared with TNF-${\alpha}$ inhibitors, non-TNF biologics were associated with higher ACR response rates; in ACR20, the OR was 1.639 for abatacept [P(OR>1) = 90.7 %], 1.871 for rituximab [P(OR>1) = 96.2 %] and 3.52 for tocilizumab [P(OR>1) = 99.9 %]. Similar trends were shown in the HAQ change comparison; the median differences (MD) were -0.259 for abatacept [P(MD<0) = 100 %], -0.160 for rituximab [P(MD\0) = 98.2 %], and -0.200 for tocilizumab [P(MD\0) = 99.3 %]. In conclusion, switching to non-TNF biologics was more effective than cycling TNF-${\alpha}$ inhibitor in TNF-IR patients.

#Rheumatoid arthritis #Inadequate response to TNF-${alpha}$ inhibitors #Comparative effectiveness #American college of rheumatology #ACR) #Health assessment questionnaire #HAQ)

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요